Orforglipron - Eli Lilly and Company
Alternative Names: GLP-1 receptor NPA - Eli Lilly and Company; Glucagon like peptide 1 receptor NPA - Eli Lilly and Company; LY-3502970; OWL 833Latest Information Update: 10 Sep 2024
At a glance
- Originator Chugai Pharmaceutical
- Developer Eli Lilly and Company
- Class Antihyperglycaemics; Fluorinated hydrocarbons; Imidazoles; Indazoles; Indoles; Ketones; Obesity therapies; Oxadiazoles; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
Most Recent Events
- 05 Sep 2024 Eli Lily and Company initiates a phase III trial for Obesity in USA (PO) (NCT06584916)
- 29 Jul 2024 Eli Lilly and Company completes a Phase-I clinical trial in Obesity in China (PO) (NCT06023095)
- 23 Jul 2024 Eli Lilly and Company completes phase-I Drug-Drug Interaction trial (In volunteers) in USA (PO) (NCT06370728)